<DOC>
	<DOCNO>NCT00477594</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy extend dose mipomersen patient familial hypercholesterolemia lipid-lowering therapy complete either 301012-CS8 ( NCT00280995 ) 301012-CS9 ( NCT00281008 ) clinical drug trial .</brief_summary>
	<brief_title>Open Label Extension ISIS 301012 ( Mipomersen ) Treat Familial Hypercholesterolemia</brief_title>
	<detailed_description>Familial Hypercholesterolemia ( FH ) autosomal dominant metabolic disorder characterize markedly elevate low density lipoprotein ( LDL ) , premature onset atherosclerosis , development xanthomata . There two distinct subpopulation high unmet medical need due lack alternative therapy : homozygote , two defective LDL receptor ( LDL-R ) gene , heterozygote history cardiovascular disease ( CVD ) maximally tolerate therapy . Treatment FH direct lower plasma level LDL-C. Mipomersen antisense drug target human apolipoprotein B ( apoB ) , principal apolipoprotein atherogenic LDL-C metabolic precursor , low density lipoprotein ( VLDL ) . Mipomersen complimentary cod region messenger ribonucleic acid ( mRNA ) apo-B . Inhibition apo-B would expect impair VLDL synthesis result lower level LDL-C . In early clinical trial , mipomersen show reduce level LDL-C recommend target level participant . This open-label extension study , consist â‰¤2-week screening period , 3 year treatment mipomersen , 24-week post-treatment follow-up period . Patients participate Cohorts A , B , C study 301012-CS9 randomized 1:1 ratio mipomersen 200 mg week ( QW ) 200 mg mipomersen every week ( QOW ) 3 year . Patients randomize mipomersen 200 mg QOW allow receive mipomersen 200 mg QW Investigator 's discretion first 52 week treatment period . Patients participate study 301012-CS8 Cohort D study 301012-CS9 receive 200 mg mipomersen QW 3 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Satisfactory completion dose Week 7 Week 15 assessment ( depend treatment dose receive ) initial study ( Protocol 301012CS8 ( NCT00280995 ) 301012CS9 ( NCT00281008 ) ) . Have new condition worsen exist condition opinion Investigator would make patient unsuitable enrollment , could interfere patient 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Familial Hypercholesterolemia</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>ISIS 301012</keyword>
	<keyword>mipomersen</keyword>
	<keyword>Open Label Extension</keyword>
</DOC>